Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Amplia Therapeutics Ltd

Healthcare AU ATX

0.12AUD
0.00(0%)

Last update at 2026-06-05T06:10:00Z

Day Range

0.120.12
LowHigh

52 Week Range

0.060.42
LowHigh

Fundamentals

  • Previous Close 0.12
  • Market Cap59.03M
  • Volume947854
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.37525M
  • Revenue TTM4.79M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 4.41M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -12.48539M -6.57203M -8.94120M -6.24244M -3.64422M
Minority interest - - - - -
Net income -7.70715M -6.57203M -4.50345M -6.29628M -3.64537M
Selling general administrative - 2.67M 2.60M 2.41M 1.70M
Selling and marketing expenses - 0.08M 0.09M - -
Gross profit -0.09214M 3.57M 4.01M - -
Reconciled depreciation - 0.09M 0.09M 0.07M 0.00321M
Ebit -13.18011M -6.79198M -4.57007M -6.18859M -3.64307M
Ebitda -13.08797M -6.78202M -4.48392M -6.11522M -3.63986M
Depreciation and amortization 0.09M 0.00996M 0.09M 0.07M 0.00321M
Non operating income net other - - - - -
Operating income -13.18011M -6.51615M -4.42497M -6.18859M -3.64307M
Other operating expenses 13.18M 10.30M 8.88M 7.48M 5.63M
Interest expense 0.02M 0.06M 0.08M 0.05M 0.00115M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 0.22M 0.15M 0.10M 0.00062M
Net interest income - 0.22M 0.07M 0.04M -0.00053M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.77823M -3.77171M -4.43774M 0.05M 0.00115M
Total revenue - 3.78M 4.45M 1.15M 1.98M
Total operating expenses 13.09M 10.09M 8.44M 7.48M 5.63M
Cost of revenue 0.09M 0.21M 0.44M - -
Total other income expense net 0.69M -0.05588M -4.51622M -0.05385M -0.00115M
Discontinued operations - - - - -
Net income from continuing ops - -6.57203M -4.50345M -6.24244M -3.64422M
Net income applicable to common shares - -6.57203M -4.50345M -6.24244M -3.64422M
Preferred stock and other adjustments - - - - -
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 41.44M 22.94M 14.85M 18.68M 24.48M
Intangible assets 7.94M 7.94M - 7.94M 7.94M
Earning assets - - - - -
Other current assets 0.41M 0.18M 0.19M 0.07M 0.05M
Total liab 1.97M 1.91M 3.43M 2.85M 2.64M
Total stockholder equity 39.47M 21.02M 11.42M 15.84M 21.85M
Deferred long term liab - - - - -
Other current liab 0.18M - 0.25M 2.40M 0.16M
Common stock 193.43M - 151.53M 151.53M 151.51M
Capital stock - 167.39M - 151.53M 151.51M
Retained earnings -152.82976M -145.53810M -139.01437M -134.72442M -128.61845M
Other liab - - - 0.00353M 0.00541M
Good will - - - - -
Other assets - - - 0.05M -
Cash 27.85M 10.86M 3.39M 9.26M 14.61M
Cash and equivalents - - - 7.98M 10.62M
Total current liabilities 1.67M 1.89M 3.40M 2.75M 0.53M
Current deferred revenue - - - -2.18115M -2.18115M
Net debt -27.51292M - -1.82359M -6.98081M -12.50811M
Short term debt 0.09M - 1.55M 2.18M 2.18M
Short long term debt - - - 2.11M -
Short long term debt total 0.34M - 1.56M 2.28M 2.10M
Other stockholder equity - - - -0.96903M -1.04165M
Property plant equipment - - - 0.18M 0.01M
Total current assets 33.04M 14.93M 6.75M 10.51M 16.53M
Long term investments - - - - -
Net tangible assets - - - 7.90M 13.91M
Short term investments - - - - -
Net receivables 4.78M - 3.18M 1.15M 1.84M
Long term debt - - - 0.00000M 2.10M
Inventory - - - 0.04M 0.03M
Accounts payable 1.40M 1.56M 1.60M 0.35M 0.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.12845M - -1.09654M -0.96903M -1.04165M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.11M 0.05M 7.99M 0.05M -7.95085M
Deferred long term asset charges - - - - -
Non current assets total 8.40M 8.01M 8.09M 8.18M 7.95M
Capital lease obligations - 0.01M - 0.17M -
Long term debt total - - - 0.09M 2.10M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - -0.00207M -0.00223M -0.05842M -0.01224M
Change to liabilities - - - -0.01073M 0.00372M
Total cashflows from investing activities -0.09622M -0.00207M -0.00223M -0.05843M -0.02664M
Net borrowings - - -0.63300M -0.06465M 2.10M
Total cash from financing activities 25.94M 14.32M -0.77298M -0.08422M 17.19M
Change to operating activities - - - - -
Net income -7.70715M -6.57203M -4.50345M -6.24244M -3.64422M
Change in cash 16.99M 7.48M -5.87137M -5.35190M 12.76M
Begin period cash flow 10.86M 3.39M 9.26M 14.61M 1.85M
End period cash flow 27.85M 10.86M 3.39M 9.26M 14.61M
Total cash from operating activities -8.73350M -6.88592M -5.12718M -5.28969M -4.40202M
Issuance of capital stock - 17.28M 0.00024M 0.02M 16.27M
Depreciation 0.09M - 0.09M 0.07M 0.00321M
Other cashflows from investing activities -0.06292M - 0.00000M -0.04079M -0.01224M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -1.10258M -0.66822M -2.04455M 0.68M -0.82543M
Sale purchase of stock - -1.33024M 0.00024M 0.02M -1.18186M
Other cashflows from financing activities -0.08901M -0.16373M -0.14022M -0.04080M 2.10M
Change to netincome - - - 0.21M 0.06M
Capital expenditures 0.03M 0.00207M 0.00223M 0.02M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.38601M -0.53413M -0.79602M 0.68M -0.82543M
Stock based compensation - - 0.09M 0.21M 0.06M
Other non cash items 0.27M -6.35180M 0.09M 0.88M -0.76101M
Free cash flow -8.76681M -6.88800M -5.12941M -5.30732M -4.41642M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ATX
Amplia Therapeutics Ltd		 - -% 0.12 - - 12.32 1.58 -1.6534
CSL
CSL Ltd		 5.32 5.75% 97.91 10.77 13.61 2.87 1.71 2.71 8.15
TLX
TELIX Pharmaceuticals Ltd		 0.42 3.26% 13.31 - 2500.00 5.43 7.40 4.23 96.65
MSB
Mesoblast Ltd		 0.03 1.49% 2.05 - 454.55 39.94 3.31 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.12 0.89% 13.65 58.83 54.95 26.44 5.14 22.38 65.68

Reports Covered

Stock Research & News

View All

Profile

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Amplia Therapeutics Ltd

90 William Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO, MD & Director 1964
Mr. Hamish George Chief Financial Officer NA
Ms. Rhiannon Jones B.Sc., Ph.D. Chief Operating Officer NA
Ms. Terrie-Anne Cock Ph.D. Head of Translational Biology NA
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD Company Sec. 1960
Dr. Frank Gelder Founding Scientist NA
Dr. James A. Taylor Ph.D. Trials Consultant 1961
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR Trials Consultant 1948
Dr. Benjamin M. Segal Clinical Consultant NA
Dr. Frederick E. Reno Ph.D. Toxicology Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.